

Montelukast Granules Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Montelukast Granules Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : Avenida 16 de Septiembre No. 301

Xaltocan - Xochimilco Mexico 16090

Telephone : +52 55 57284444 Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required

Other hazards

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Montelukast	151767-02-1	>= 0.1 -< 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.





Montelukast Granules Formulation

SDS Number: Date of last issue: 20.03.2023 Version Revision Date: 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and Contact with dust can cause mechanical irritation or drying of

delayed

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders

No special precautions are necessary for first aid responders.

Notes to physician

Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

Evacuate area.

Special protective equipment

for fire-fighters

Wear self-contained breathing apparatus for firefighting if

necessary.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: : tive equipment and emergency procedures

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to



Montelukast Granules Formulation

Date of last issue: 20.03.2023 Version Revision Date: SDS Number: 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation Use only with adequate ventilation.

Do not breathe dust. Advice on safe handling

Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Materials to avoid Do not store with the following product types:

Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Montelukast	151767-02-1	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm ²	Internal

Engineering measures All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices).



Montelukast Granules Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 20.03.2023

 4.1
 26.09.2023
 23006-00023
 Date of first issue: 17.10.2014

Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or

exposure assessment demonstrates exposures outside the

recommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower : No data available



Montelukast Granules Formulation

SDS Number: Date of last issue: 20.03.2023 Version Revision Date: 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

flammability limit

No data available Vapor pressure

Relative vapor density No data available

Relative density No data available

Density No data available

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

No data available

Autoignition temperature No data available

Decomposition temperature No data available

Viscosity

No data available Viscosity, kinematic

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid Heat, flames and sparks.

Avoid dust formation.

Incompatible materials

Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact



Montelukast Granules Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

Acute toxicity

Not classified based on available information.

Components:

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 5,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Skin corrosion/irritation

Not classified based on available information.

Components:

Montelukast:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Montelukast:

Species : Rabbit

Result : Severe irritation

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Montelukast:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Product:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts



Montelukast Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

Components:

Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Product:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

Dose : 200 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks

Dose : 100 mg/kg body weight





Montelukast Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

Result : negative

Components:

Montelukast:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Product:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL Parent: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL Parent: 200 mg/kg body weight

Symptoms: Reduced fertility

Components:

Montelukast:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL: 200 mg/kg body weight

Symptoms: Reduced fertility

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

Symptoms: Reduced fertility



Montelukast Granules Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Montelukast:

Species : Monkey, male and female

NOAEL : 150 - 300 mg/kg

Application Route : Oral Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Product:

Skin contact : Remarks: May irritate skin.
Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhea, Fever

Components:

Montelukast:

Skin contact : Remarks: May irritate skin. Eye contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhea, Fever

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Montelukast:





Montelukast Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.0778 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 0.0675 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mq/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 0.073 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility.

NOEC (Cyprinodon variegatus (sheepshead minnow)): 0.0816

mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 0.23 mg/l

Exposure time: 21 d

Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility.

Persistence and degradability

Components:

Montelukast:

Biodegradability : Result: not rapidly degradable

Biodegradation: 0 % Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(21.7 h)



Montelukast Granules Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

Bioaccumulative potential

Components:

Montelukast:

Partition coefficient: n-

octanol/water

log Pow: > 4.3

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills.

Not applicable

The ingredients of this product are reported in the following inventories:





Montelukast Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 26.09.2023 Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response: ELx - Loading rate associated with x% response: EmS - Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals: SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States): UN - United Nations: UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/



Montelukast Granules Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 4.1 26.09.2023 23006-00023 Date of first issue: 17.10.2014

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8